https://www.thebodypro.com/category/managing-hiv-drug-resistance-pro
HIV Treatment Strategies

Managing HIV Drug Resistance

The Latest

scientists analyzing
Features

Fostemsavir, at Last: A New Treatment Option for Extensive HIV Drug Resistance

Most people living with HIV will never need fostemsavir. But for those who do, the drug can be a life-saver—and that is pretty epic.

By David Alain Wohl, M.D.
human touch
News

This Week in HIV Research: The Human Touch

Nov. 5, 2020: Success of direct referrals at re-linking people to HIV care; stable housing = viral suppression; modern-day rates of virologic failure; how pharmacy type affects HIV treatment outcomes.

By Barbara Jungwirth and Myles Helfand
maze
News

This Week in HIV Research: A Metabolic Maze

Oct. 29, 2020: Diabetes incidence on INSTIs vs. NNRTIs vs. protease inhibitors; can NRTIs fight diabetes?; from TDF to TAF in HIV/HBV-coinfected people; assessing neurocognitive impacts of older two-drug regimens.

By Barbara Jungwirth and Myles Helfand
COVID-19 mask profile
News

This Week in HIV Research: The Real-World Effects of COVID-19

Oct. 22, 2020: Impact of COVID-19 shutdowns on HIV viral suppression; unsuppressed HIV viral load despite no treatment failure; point-of-care rapid testing vs. lab testing; it's not about "what," it's about "when."

By Barbara Jungwirth and Myles Helfand
injectable
Interviews

What Are the New HIV Treatment and Prevention Drugs Under Development in 2020?

Richard Jefferys of Treatment Action Group discusses the pipeline for new modalities being explored for treatment, PrEP, vaccine, and cure.

By Terri Wilder, M.S.W.
doctor walking away
News

This Week in HIV Research: How to Fix Our Dwindling HIV Workforce

April 23, 2020: The corps of front-line care providers with HIV-specific experience is aging and retiring, leaving behind a growing need for quality care. We examine recent research and analysis that both describes that need and offers interventions to meet it.

By Barbara Jungwirth and Myles Helfand
two elderly people sitting and looking at water
News

This Week in HIV Research: Our Attunement to Aging

Jan. 30, 2020: Polypharmacy vs. drug interaction risk among people living with HIV as they age; cost-effectiveness of ibalizumab; PrEP persistence on Medicaid vs. private health coverage.

By Barbara Jungwirth and Myles Helfand
Actor Jonathan Del Arco portrays a Borg in a 1987 episode of Star Trek: The Next Generation
News

This Week in HIV Research: Resistance (Testing) Is Futile

Dec. 5, 2019: The value of pre-treatment drug resistance testing; resistance rates among viremic Americans; persistent pneumonia incidence among people with HIV; mixed HIV prevention results for the U.S. National HIV Strategy.

By Barbara Jungwirth and Myles Helfand
The DAWNING Study photo illo
Features

DAWNING Study Casts New Light on the Details of Resistance

The findings will help providers manage patients who have known or potential resistance to NRTIs, but who we want to place on a simplified antiretroviral regimen.

By David Alain Wohl, M.D.
Anchor on edge of boat
News

This Week in HIV Research: Weighing Anchor on NRTI-Free Treatment

June 27, 2019: Long-term viability of NRTI-free salvage therapy; factors associated with HIV treatment interruption; evolution of frailty risk among older people; skin and soft tissue infections among people with HIV.

By Barbara Jungwirth and Myles Helfand